Health Professional Radio - Podcast

Dr. Neal D. Shore discusses the recent (July 2019) FDA approval of Bayer's NUBEQA® (darolutamide) for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC). The approval is based on the Phase III ARAMIS trial, published earlier this year in the New England Journal of Medicine, the largest Phase III study in nmCRPC to date.